Geode Capital Management
ENTA icon

Geode Capital Management’s Enanta Pharmaceuticals ENTA Stock Holding History

Geode Capital Management’s Portfolio ENTA Stock Details ENTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$11.3M Buy
776,634
+51,573
+7% +$693K ﹤0.01% 2468
2026
Q1 		$9.16M Buy
725,061
+79,270
+12% +$1.06M ﹤0.01% 2433
2025
Q4 		$10.2M Buy
645,791
+152,597
+31% +$1.94M ﹤0.01% 2406
2025
Q3 		$5.9M Buy
493,194
+7,397
+2% +$59.1K ﹤0.01% 2696
2025
Q2 		$3.67M Sell
485,797
-8,408
-2% -$50.6K ﹤0.01% 2888
2025
Q1 		$2.73M Buy
494,205
+16,974
+4% +$105K ﹤0.01% 2931
2024
Q4 		$2.74M Sell
477,231
-120
-0% -$1.15K ﹤0.01% 3020
2024
Q3 		$4.95M Buy
477,351
+14,575
+3% +$191K ﹤0.01% 2762
2024
Q2 		$6M Buy
462,776
+20,704
+5% +$279K ﹤0.01% 2624
2024
Q1 		$7.72M Buy
442,072
+12,835
+3% +$170K ﹤0.01% 2479
2023
Q4 		$4.04M Buy
429,237
+19,537
+5% +$182K ﹤0.01% 2815
2023
Q3 		$4.58M Buy
409,700
+5,897
+1% +$95K ﹤0.01% 2685
2023
Q2 		$8.64M Buy
403,803
+8,727
+2% +$257K ﹤0.01% 2374
2023
Q1 		$16M Buy
395,076
+16,135
+4% +$770K ﹤0.01% 1945
2022
Q4 		$17.6M Buy
378,941
+15,960
+4% +$728K ﹤0.01% 1853
2022
Q3 		$18.8M Buy
362,981
+16,709
+5% +$976K ﹤0.01% 1773
2022
Q2 		$16.4M Sell
346,272
-6,444
-2% -$350K ﹤0.01% 1900
2022
Q1 		$25.1M Buy
352,716
+16,708
+5% +$1.09M ﹤0.01% 1736
2021
Q4 		$25.1M Buy
336,008
+2,215
+0.7% +$174K ﹤0.01% 1801
2021
Q3 		$19M Buy
333,793
+3,384
+1% +$167K ﹤0.01% 1994
2021
Q2 		$14.5M Buy
330,409
+17,865
+6% +$875K ﹤0.01% 2199
2021
Q1 		$15.4M Buy
312,544
+26,964
+9% +$1.34M ﹤0.01% 2044
2020
Q4 		$12M Buy
285,580
+10,594
+4% +$466K ﹤0.01% 2041
2020
Q3 		$12.6M Buy
274,986
+8,269
+3% +$401K ﹤0.01% 1820
2020
Q2 		$13.4M Buy
266,717
+7,942
+3% +$411K ﹤0.01% 1758
2020
Q1 		$13.3M Buy
258,775
+27,220
+12% +$1.45M ﹤0.01% 1557
2019
Q4 		$14.3M Sell
231,555
-557
-0.2% -$34.5K ﹤0.01% 1764
2019
Q3 		$13.9M Buy
232,112
+12,811
+6% +$952K ﹤0.01% 1703
2019
Q2 		$18.5M Buy
219,301
+6,858
+3% +$617K ﹤0.01% 1539
2019
Q1 		$20.3M Buy
212,443
+13,741
+7% +$1.23M 0.01% 1409
2018
Q4 		$14.1M Buy
198,702
+16,732
+9% +$1.28M ﹤0.01% 1533
2018
Q3 		$15.6M Buy
181,970
+11,572
+7% +$1.16M ﹤0.01% 1591
2018
Q2 		$19.7M Buy
170,398
+18,078
+12% +$1.8M 0.01% 1364
2018
Q1 		$12.3M Buy
152,320
+12,892
+9% +$992K ﹤0.01% 1614
2017
Q4 		$8.18M Buy
139,428
+1,798
+1% +$90K ﹤0.01% 1887
2017
Q3 		$6.44M Buy
137,630
+1,210
+0.9% +$48.6K ﹤0.01% 2043
2017
Q2 		$4.91M Buy
136,420
+15,851
+13% +$507K ﹤0.01% 2155
2017
Q1 		$3.71M Sell
120,569
-12,015
-9% -$374K ﹤0.01% 2283
2016
Q4 		$4.44M Buy
132,584
+6,436
+5% +$184K ﹤0.01% 2138
2016
Q3 		$3.36M Buy
126,148
+9,335
+8% +$217K ﹤0.01% 2220
2016
Q2 		$2.58M Sell
116,813
-13,505
-10% -$353K ﹤0.01% 2323
2016
Q1 		$3.83K Buy
130,318
+22,248
+21% +$619K ﹤0.01% 2043
2015
Q4 		$3.57M Buy
108,070
+12,457
+13% +$406K ﹤0.01% 2111
2015
Q3 		$3.46M Buy
95,613
+1,960
+2% +$84.2K ﹤0.01% 2084
2015
Q2 		$4.21M Buy
93,653
+8,322
+10% +$324K ﹤0.01% 2004
2015
Q1 		$2.61M Buy
85,331
+9,408
+12% +$366K ﹤0.01% 2274
2014
Q4 		$3.86M Buy
75,923
+20,204
+36% +$905K ﹤0.01% 1991
2014
Q3 		$2.2M Buy
55,719
+13,320
+31% +$531K ﹤0.01% 2306
2014
Q2 		$1.83M Buy
42,399
+12,456
+42% +$475K ﹤0.01% 2426
2014
Q1 		$1.2M Buy
29,943
+8,596
+40% +$312K ﹤0.01% 2667
2013
Q4 		$582K Sell
21,347
-163
-0.8% -$3.95K ﹤0.01% 3018
2013
Q3 		$493K Buy
21,510
+689
+3% +$13.2K ﹤0.01% 2956
2013
Q2 		$369K Buy
+20,821
New +$406K ﹤0.01% 3006

Other funds holding ENTA

JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KAM
Krensavage Asset Management New York $263M AUM 66.99% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SSC
Spruce Street Capital New York $510M AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Geode Capital Management's ENTA Position: Q2 2026 in Review

Geode Capital Management increased its Enanta Pharmaceuticals (ENTA) stake by 7.1% in Q2 2026, buying an estimated $693K and bringing the position to 776,634 shares worth $11.3M. The position accounts for ﹤0.01% of the portfolio, ranked #2468.

Geode Capital Management first reported a position in ENTA in Q2 2013 and has held it in 53 quarters since. The position peaked at $25.1M in Q4 2021. 122 funds tracked by Wall St. Rank hold ENTA as of Q2 2026.

  • Geode Capital Management held 776,634 shares of Enanta Pharmaceuticals worth $11.3M as of Q2 2026.
  • Geode Capital Management bought 51,573 Enanta Pharmaceuticals shares in Q2 2026, an estimated $693K.
  • Enanta Pharmaceuticals made up ﹤0.01% of Geode Capital Management's portfolio in Q2 2026, its #2468 holding.
  • Geode Capital Management first reported a position in Enanta Pharmaceuticals in Q2 2013 and has held it in 53 quarters since.
  • Geode Capital Management's Enanta Pharmaceuticals position peaked at $25.1M in Q4 2021.
  • 122 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q2 2026.

Based on Geode Capital Management's 13F filing for Q2 2026, filed 12 Aug 2026.